In the following interview, co-author and panel member Benjamin M. Brucker, MD, provides a detailed walkthrough of these guidelines and discusses their practical implications for clinicians.He ...

Discrepancies between the 2 training pathways extend beyond residency, with differences in both practice patterns and physician demographics. Research across various specialties and with diverse ...

"At the end of the day, it's going to be unlikely that we're going to use a single therapy for all of our patients," says Vignesh T. Packiam, MD. There has been an explosion of treatment options in ...

Panelists discuss emerging data comparing bladder-sparing therapies to radical cystectomy in BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC), highlighting the nuanced trade-offs in ...

Panelists discuss how leveraging resources such as patient assistance programs, insurance navigators, clinical trial databases, advocacy groups, and oncology support services can help overcome access ...

In the following interview, senior author Madhur Nayan, MD, PhD, walks through key findings from the validation of the tool, which were recently presented at the American Urological Association Annual ...

In a recent interview, Rebecca A. Campbell, MD, a urologic oncology fellow at Cleveland Clinic in Cleveland, Ohio, discussed concrete steps to mitigate gender-based disparities in Altmetric Attention ...

Physician Summary: Reflections on Progress and Looking Ahead in NMIBC – AUA 2025. As we reflect on the progress made in the treatment of non–muscle-invasive bladder cancer (NMIBC) leading up to AUA ...

In a recent interview, Stacy Loeb, MD, MSc, PhD (Hon), a professor in the departments of urology and population health at NYU Grossman School of Medicine and Perlmutter Cancer Center in New York, New ...

Preliminary data from an expansion cohort of the phase 1b STELLAR-002 trial (NCT05176483)were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois. 1 ...

Panelists discuss how the ZIRCON trial demonstrated high positive predictive value (> 90%) for identifying clear cell renal cell carcinoma using a new molecular imaging agent, though negative ...

Study findings directly inform the treatment of Black men with prostate cancer. Results confirm drug efficacy in this specific population. Data support equal eligibility of Black men for darolutamide ...